INV-102 is under clinical development by Invirsa and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INV-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INV-102 is under development for the treatment of adenovirus associated acute keratoconjunctivitis, dry eye disease and upper respiratory tract infections. It is administered as an ophthalmic solution for acute keratoconjunctivitis. The drug candidate is derived from a naturally occurring small molecule.
Invirsa developing lead compound (INV-102), augments the body’s response to DNA damage and improves cell stability against common infectious diseases, viral pneumonia and dry eye. Invirsa is headquartered in Columbus, Ohio, the US.
For a complete picture of INV-102’s drug-specific PTSR and LoA scores, buy the report here.